metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)
versus paclitaxel followed by doxorubicin plus cyclophosphamide, pertuzumab plus trastuzumab, placebo
	paclitaxel followed by doxorubicin plus cyclophosphamide
	IMpassion-050, 2022 J Clin Oncol 2022; 40:2946-2956-. European Society for Medical Oncology NCT03726879	RCT	es-BC - HER2 positive - (neo)adjuvant (NA)	Atezolizumab plus SOC	Placebo plus SOC	Patients ≥ 18 years old with a primary tumor of > 2 cm, positive lymph node status and histologically confirmed Early Her2-Positive Breast Cancer	226 / 228	low	inconclusive	inconclusive 1 % decrease in pCR (PE) inconclusive 33 % decrease in pCR (PE) Atezolizumab with neoadjuvant dose-dense doxorubicin/cyclophosphamide–paclitaxel and PH for high-risk, HER2-positive early breast cancer did not increase pCR rates versus placebo in the ITT or PD-L1–positive populations

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

NCT03726879

RCT

es-BC - HER2 positive - (neo)adjuvant (NA)

Atezolizumab plus SOC

Placebo plus SOC

Patients ≥ 18 years old with a primary tumor of > 2 cm, positive lymph node status and histologically confirmed Early Her2-Positive Breast Cancer

226 / 228

inconclusive 1 % decrease in pCR (PE)
inconclusive 33 % decrease in pCR (PE)

Atezolizumab with neoadjuvant dose-dense doxorubicin/cyclophosphamide–paclitaxel and PH for high-risk, HER2-positive early breast cancer did not increase pCR rates versus placebo in the ITT or PD-L1–positive populations

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus paclitaxel followed by doxorubicin plus cyclophosphamide, pertuzumab plus trastuzumab, placebo

paclitaxel followed by doxorubicin plus cyclophosphamide